{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:24:56Z","timestamp":1793049896440,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.bbrc.2021.02.110","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T15:13:57Z","timestamp":1614870837000},"page":"150-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma"],"prefix":"10.1016","volume":"549","author":[{"given":"Min","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1569-2604","authenticated-orcid":false,"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2021.02.110_bib1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbrc.2021.02.110_bib2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.bbrc.2021.02.110_bib3","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1182\/blood-2013-02-483073","article-title":"Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results","volume":"122","author":"Gay","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2021.02.110_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.drudis.2019.11.008","article-title":"New generation drugs for treatment of multiple myeloma","volume":"25","author":"Alanazi","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbrc.2021.02.110_bib5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2021.02.110_bib6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kronke","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2021.02.110_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1249543","article-title":"Medicine. How thalidomide works against cancer","volume":"343","author":"Stewart","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2021.02.110_bib8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2021.02.110_bib9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A\u00a0novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2021.02.110_bib10","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41401-020-0367-9","article-title":"The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L","volume":"41","author":"Hao","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbrc.2021.02.110_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.omto.2020.06.013","article-title":"A\u00a0cereblon modulator CC-885 induces CRBN- and p97-dependent PLK1 degradation and synergizes with volasertib to suppress lung cancer","volume":"18","author":"Li","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.bbrc.2021.02.110_bib12","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1038\/s41467-018-07185-y","article-title":"Proteome-wide analysis of USP14 substrates revealed its role in hepatosteatosis via stabilization of FASN","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2021.02.110_bib13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nrc3090","article-title":"Cyclin D as a therapeutic target in cancer","volume":"11","author":"Musgrove","year":"2011","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.bbrc.2021.02.110_bib14","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1073\/pnas.1700949114","article-title":"p97\/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates","volume":"114","author":"Nguyen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2021.02.110_bib15","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1038\/onc.2013.137","article-title":"Signaling through cyclin D-dependent kinases","volume":"33","author":"Choi","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2021.02.110_bib16","article-title":"Cyclin D\/CDK4\/6 activity controls G1 length in mammalian cells","volume":"13","author":"Dong","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2021.02.110_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrc3120","article-title":"RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis","volume":"11","author":"Lipkowitz","year":"2011","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.bbrc.2021.02.110_bib18","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-019-0362-y","article-title":"Development of targeted protein degradation therapeutics","volume":"15","author":"Chamberlain","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbrc.2021.02.110_bib19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2019.06.004","article-title":"Molecular mechanisms of cereblon-based drugs","volume":"202","author":"Asatsuma-Okumura","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2021.02.110_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2021.02.110_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/bs.acr.2020.02.002","article-title":"Cyclin D-CDK4\/6 functions in cancer","volume":"148","author":"Gao","year":"2020","journal-title":"Adv. Canc. Res."},{"key":"10.1016\/j.bbrc.2021.02.110_bib22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1517\/13543784.2015.993753","article-title":"The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma","volume":"24","author":"Altenburg","year":"2015","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.bbrc.2021.02.110_bib23","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.3109\/10428194.2015.1030641","article-title":"Phase 1\/2 study of cyclin-dependent kinase (CDK)4\/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed\/refractory multiple myeloma","volume":"56","author":"Niesvizky","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbrc.2021.02.110_bib24","article-title":"Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL","author":"Martin","year":"2020","journal-title":"Ann. Oncol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21003375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21003375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:03:20Z","timestamp":1757765000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X21003375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":24,"alternative-id":["S0006291X21003375"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.02.110","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.02.110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}